- Home
- MMA vs LPCN Comparison
MMA vs LPCN Comparison
Compare MMA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMA
- LPCN
- Stock Information
- Founded
- MMA 2013
- LPCN 1997
- Country
- MMA Australia
- LPCN United States
- Employees
- MMA N/A
- LPCN N/A
- Industry
- MMA
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- MMA
- LPCN Health Care
- Exchange
- MMA Nasdaq
- LPCN Nasdaq
- Market Cap
- MMA 20.2M
- LPCN 18.2M
- IPO Year
- MMA 2024
- LPCN N/A
- Fundamental
- Price
- MMA $1.49
- LPCN $2.73
- Analyst Decision
- MMA
- LPCN Strong Buy
- Analyst Count
- MMA 0
- LPCN 1
- Target Price
- MMA N/A
- LPCN $8.00
- AVG Volume (30 Days)
- MMA 466.0K
- LPCN 33.9K
- Earning Date
- MMA 01-01-0001
- LPCN 11-07-2025
- Dividend Yield
- MMA N/A
- LPCN N/A
- EPS Growth
- MMA N/A
- LPCN N/A
- EPS
- MMA N/A
- LPCN N/A
- Revenue
- MMA $903,377.00
- LPCN $4,208,119.00
- Revenue This Year
- MMA N/A
- LPCN N/A
- Revenue Next Year
- MMA N/A
- LPCN N/A
- P/E Ratio
- MMA N/A
- LPCN N/A
- Revenue Growth
- MMA N/A
- LPCN N/A
- 52 Week Low
- MMA $0.60
- LPCN $2.52
- 52 Week High
- MMA $3.07
- LPCN $6.16
- Technical
- Relative Strength Index (RSI)
- MMA 50.23
- LPCN 41.80
- Support Level
- MMA $1.45
- LPCN $2.52
- Resistance Level
- MMA $1.65
- LPCN $2.92
- Average True Range (ATR)
- MMA 0.11
- LPCN 0.14
- MACD
- MMA -0.02
- LPCN -0.03
- Stochastic Oscillator
- MMA 36.92
- LPCN 26.79
About MMA Alta Global Group Limited
Mixed Martial Arts Group Ltd formerly Alta Global Group Ltd is a technology company engaged in the provision and administration of mixed martial arts training programs, and gym programs. It provides subscription-based products and services, offering both B2B SaaS solutions and B2C products and programs, covering online engagement, online content, and immersive in-gym experiences. The company's business units are; Trainalta.com; Mixed Martial Arts.com; and Hype.Co, Mobile Marketing solution. Its Alta Platform serves as a comprehensive solution for martial arts and combat sports, offering a blend of four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.